Literature DB >> 28534147

Hypothyroidism in hospitalized elderly patients: a sign of worse prognosis.

N Sforza1, J Rosenfarb1, R Rujelman1, M Rosmarin1, E Blanc1, C Frigerio2, P Fossati2, D Caruso3, C Faingold1, T Meroño4, G Brenta5.   

Abstract

PURPOSE: Overt hypothyroidism has adverse clinical consequences and might worsen prognosis in critically ill elderly patients. However, the difficult interpretation of thyroid function tests (TFT) due to non-thyroidal illness (NTI) has led to discouragement of screening for thyroid dysfunction. Our aim was to determine the prevalence of TFT compatible with hypothyroidism and to study its influence on mortality among hospitalized elderly patients.
METHODS: In this prospective study we consecutively included all patients ≥60 years admitted by the Internal Medicine Department to the hospital ward (n = 451) of the Cesar Milstein Hospital in Buenos Aires, Argentina. TFT were done on day 1 and 8. Thyroid function categories were defined as overt and subclinical hypothyroidism, overt and subclinical hyperthyroidism, euthyroidism and NTI. Stage of chronic kidney disease (CKD), Adult Comorbidity Evaluation (ACE)-27, and intra-hospital mortality were recorded. The association between mortality and TFT categories was studied by Cox regression.
RESULTS: Out of 451 patients (77.0 ± 7.9 years, 54% females) 76% were categorized as NTI, 4% as overt hypothyroid, 10% as subclinical hypothyroid, 1% as subclinical hyperthyroid and 9% as euthyroid. Overt hypothyroid patients showed significantly higher mortality than the rest of the groups (25%, p < 0.05) while ACE-27 was similar among all of them (p = 0.658). In addition, patients within the overt hypothyroid category showed a higher mortality rate than NTI in a model adjusted by Stage 5-CKD, ACE-27, sex and age [HR 3.1 (1.14-8.41), p < 0.026].
CONCLUSION: Overt hypothyroidism during hospitalization was associated with elevated mortality. Further studies would reveal if TFT alterations compatible with hypothyroidism should be diagnosed/treated in hospitalized elderly patients.

Entities:  

Keywords:  Elderly; Hospitalization; Hypothyroidism; Non-thyroidal disease; Thyroid function tests

Mesh:

Year:  2017        PMID: 28534147     DOI: 10.1007/s40618-017-0690-2

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

Review 1.  Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view of current evidence, should be treated with appropriate replacement therapies.

Authors:  Leslie J De Groot
Journal:  Crit Care Clin       Date:  2006-01       Impact factor: 3.598

2.  Thyroid function tests and mortality in aged hospitalized patients: a 7-year prospective observational study.

Authors:  Pedro Iglesias; Elena Ridruejo; Angélica Muñoz; Florentino Prado; María Cruz Macías; María Teresa Guerrero; Pilar Tajada; Carmen García-Arévalo; Juan José Díez
Journal:  J Clin Endocrinol Metab       Date:  2013-10-30       Impact factor: 5.958

3.  Diagnosis of unrecognized primary overt hypothyroidism in the ED.

Authors:  Ying-Ju Chen; Sen-Kuang Hou; Chorng-Kuang How; Chii-Hwa Chern; Hong-Chang Lo; David Hung-Tsang Yen; Chun-I Huang; Chen-Hsen Lee
Journal:  Am J Emerg Med       Date:  2010-03-25       Impact factor: 2.469

4.  Subclinical Thyroid Dysfunction and Depressive Symptoms among the Elderly: A Prospective Cohort Study.

Authors:  Manuel R Blum; Liselotte W Wijsman; Vanessa S Virgini; Douglas C Bauer; Wendy P J den Elzen; J Wouter Jukema; Brendan M Buckley; Anton J M de Craen; Patricia M Kearney; David J Stott; Jacobjin Gussekloo; Rudi G J Westendorp; Simon P Mooijaart; Nicolas Rodondi
Journal:  Neuroendocrinology       Date:  2015-07-14       Impact factor: 4.914

Review 5.  Age- and race-based serum thyrotropin reference limits.

Authors:  Martin I Surks; Laura Boucai
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

Review 6.  Medications that distort in vitro tests of thyroid function, with particular reference to estimates of serum free thyroxine.

Authors:  Jim R Stockigt; Chen-Fee Lim
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

7.  Thyrotropin concentration predicts outcome in critical illness.

Authors:  P M Rothwell; Z F Udwadia; P G Lawler
Journal:  Anaesthesia       Date:  1993-05       Impact factor: 6.955

8.  Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism.

Authors:  Martin I Surks; Joseph G Hollowell
Journal:  J Clin Endocrinol Metab       Date:  2007-10-02       Impact factor: 5.958

9.  Non-thyroidal illness syndrome and short-term survival in a hospitalised older population.

Authors:  Sara Tognini; Francesca Marchini; Angela Dardano; Antonio Polini; Marco Ferdeghini; Maido Castiglioni; Fabio Monzani
Journal:  Age Ageing       Date:  2009-11-16       Impact factor: 10.668

10.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

View more
  3 in total

1.  Irisin levels increase after treatment in patients with newly diagnosed Hashimoto thyroiditis.

Authors:  Z A Uc; S Gorar; S Mizrak; S Gullu
Journal:  J Endocrinol Invest       Date:  2018-05-18       Impact factor: 4.256

2.  Pre-admission TSH levels predict long-term mortality in adults treated for hypothyroidism.

Authors:  Amit Akirov; Tzipora Shochat; Amir Shechvitz; Ilan Shimon; Talia Diker-Cohen; Eyal Robenshtok
Journal:  Endocrine       Date:  2017-10-20       Impact factor: 3.633

3.  Relevance of TSH evaluation in elderly in-patients with non-thyroidal illness.

Authors:  J Rosenfarb; N Sforza; R Rujelman; Y Morosan Allo; C Parisi; E Blanc; C Frigerio; P Fossati; D Caruso; C Faingold; T Meroño; G Brenta
Journal:  J Endocrinol Invest       Date:  2018-10-26       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.